{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:52:35Z","timestamp":1761947555429},"reference-count":14,"publisher":"Wiley","issue":"s127","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["APMIS"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p>Antineutrophil cytoplasmic antibodies (ANCA) levels have been thought to follow disease activity, with levels being high at presentation, declining with treatment and increasing just before relapse. However, we have shown that ANCA often persist for many years in patients with clinically inactive Wegener's granulomatosis. ANCA assays are less sensitive for treated disease than for active disease, and the levels in treated patients produce different results in different assay systems. ANCA often persist for years without relapse, and the risk of relapse probably depend on levels that are critical for any individual patient. The capture enzyme\u2010linked immunosorbent assays may be more sensitive in detecting early relapse. Relapse is more common when ANCA levels are high but, although elevated, ANCA levels are lower in relapse than at presentation. Standardized ANCA levels for the definitions of remission and relapse may not be possible, and the optimal ANCA testing protocol for treated disease remains unclear.<\/jats:p>","DOI":"10.1111\/j.1600-0463.2009.02479.x","type":"journal-article","created":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T07:22:14Z","timestamp":1243840934000},"page":"60-62","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Most proteinase3\u2010 and myeloperoxidase\u2010antineutrophil cytoplasmic antibodies enzyme\u2010linked immunosorbent assays perform less well in treated small\u2010vessel vasculitis than in active disease"],"prefix":"10.1111","volume":"117","author":[{"given":"JUDY","family":"SAVIGE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MICHELLE","family":"TREVISIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MATTHEW","family":"HAYMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WENDY","family":"POLLOCK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"606","article-title":"Segmental necrotising glomerulonephritis with antineutrophil antibody","volume":"285","author":"Davies DJ","year":"1982","journal-title":"possible arbovirus aetiology?"},{"key":"e_1_2_6_3_2","first-page":"425","article-title":"Autoantibodies against neutrophils and monocytes","volume":"1","author":"Van Der Woude FJ","year":"1985","journal-title":"tool for diagnosis and marker of disease activity in Wegener's granulomatosis"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)90591-5"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360312"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/111.4.507"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)65300-2"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.6.1888.1888"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806233182504"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.23"},{"key":"e_1_2_6_11_2","first-page":"209","article-title":"Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity","volume":"244","author":"Franssen C","year":"1998","journal-title":"distinct difference between patients with antiproteinase 3 and antimyeloperoxidase autoantibodies"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215918"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1309\/F6L4C48RHFMT4AAU"},{"key":"e_1_2_6_14_2","first-page":"769","article-title":"Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis","volume":"10","author":"Segelmark M","year":"2003","journal-title":"Clin Diag Lab Immunol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000093256.18266.22"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0463.2009.02479.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0463.2009.02479.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:28:45Z","timestamp":1694626125000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0463.2009.02479.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":14,"journal-issue":{"issue":"s127","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1600-0463.2009.02479.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0463.2009.02479.x","archive":["Portico"],"relation":{},"ISSN":["0903-4641","1600-0463"],"issn-type":[{"value":"0903-4641","type":"print"},{"value":"1600-0463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"2009-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}